Immune System Diseases Clinical Trial
Official title:
Evaluation of the Impact of the HLNatural, Inc. Immune Support Product in Reducing the Length of Cold Symptoms in Adults Suffering From the Common Cold
According to the Centers of Disease Control and Prevention (CDC) adults will have an average of 2-3 colds per year. Most colds will last approximately 7-10 days. The symptoms of colds could include cough, sore throat, runny nose, body aches, fevers, headaches and fatigue. A cold can affect your activity such as going to work, interrupting your sleep and your day to day activities. The test product contains all natural ingredients which have been combined into a powder to be taken in water at the sign of a cold.
At the onset of a cold, mix 1 packet of the drink-mix product in 6-8 oz. of hot water. Drink the drink mix twice a day until symptoms are gone or 18 days, whichever comes first. 1. Complete the screening survey. 2. Sign the eConsent if approved. 3. Complete the baseline survey, demographic form, and Medication and Supplements form. 4. Receive test product and log into study portal and complete supplement receipt form. This will mark the start of your participation in this study. 5. Once you have a cold, complete the symptom survey. 6. Take test product. 7. Write down any adverse or ill effects any time after taking the test product. 8. Record if you took any additional medications or supplements daily during the course of your cold. 9. Note any final adverse events and complete the exit form. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03663933 -
Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
|
Phase 2 | |
Completed |
NCT03563066 -
Effect of Benralizumab in Atopic Dermatitis
|
Phase 2 | |
Recruiting |
NCT04339777 -
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
|
Phase 2 | |
Not yet recruiting |
NCT05969821 -
Clonal Hematopoiesis of Immunological Significance
|
||
Completed |
NCT02916888 -
A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists
|
N/A | |
Completed |
NCT02527187 -
Determination of the Sensitivity and Specificity of Prick Test Betula Verrucosa
|
Phase 2 | |
Completed |
NCT01441076 -
Anakinra for Behcet s Disease
|
Phase 1/Phase 2 | |
Completed |
NCT01472263 -
Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases
|
Phase 3 | |
Completed |
NCT03720470 -
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
|
Phase 3 | |
Suspended |
NCT04642066 -
Cold Water Immersion and Atherosclerosis, Inflammation, Fat Accumulation and Lipid Profile Parameters
|
N/A | |
Completed |
NCT02294552 -
Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
|
Phase 2 | |
Completed |
NCT01727973 -
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
|
Phase 1/Phase 2 | |
Recruiting |
NCT03344094 -
Mechanism of Action of Ocrelizumab in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05445284 -
Group Education Trial to Improve Transition for Parents of Adolescents With T1D
|
N/A | |
Recruiting |
NCT06104111 -
Epigenetic Memory of Vitamin D Supplementation
|
Phase 1 | |
Not yet recruiting |
NCT05616117 -
Next-generation Effects of Vitamin D Supplementation in Pregnancy
|
||
Completed |
NCT01510626 -
Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center
|
Phase 1 | |
Completed |
NCT01490177 -
Single Center Food Allergy Oral Immunotherapy Study
|
Phase 1 | |
Completed |
NCT03922087 -
No-worry Baby Project
|
||
Completed |
NCT03688074 -
Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)
|
Phase 2 |